Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Investor Video; BioSante Presentation at Cancer Immunotherapy ConferenceInvestorideas.com, an investor research portal specialized in sector investing including biotech and pharma stocks, features an investor video featuring showcase company BioSante Pharmaceuticals, Inc. .
By: Investorideas BioSante Pharmaceutical’ Point Roberts, WA, LINCOLNSHIRE, Ill –November 30, 2010 (Investorideas.com Newswire) Investorideas.com, an investor research portal specialized in sector investing including biotech and pharma stocks, features an investor video featuring showcase company BioSante Pharmaceuticals, Inc. . The video, featuring Stephen M. Simes, President and CEO, was recorded during “Cancer Immunotherapy: Mr. Simes reports, “There are fifteen BioSante cancer vaccine Phase I and Phase II studies ongoing in different cancers.” Watch BioSante’s segment on Cancer Vaccines for the Cancer Immunotherapy Conference the following link is provided: http://www.biobusiness.tv/ Highlights from the Cancer Vaccines Product Page: Read the Full info at: http://www.biosantepharma.com/ BioSante Pharmaceuticals Inc. is developing a pipeline of Immunotherapies (cancer vaccines). BioSante’s cancer vaccines use cell lines that are genetically modified to secrete granulocyte- Currently, BioSante’s Cancer Vaccines are in various Phase I and Phase II cancer clinical trials and may represent the widest portfolio (cancer types) of cancer vaccines in development. Studies are conducted primarily at Johns Hopkins Cancer Center and are sponsored/funded by The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, various philanthropies, foundations and the National Cancer Institute Cancer Types Being Studied: • •Leukemia ◦Chronic Myeloid Leukemia (CML) ◦Acute Myeloid Leukemia (AML) •Pancreatic Cancer •Breast Cancer •Multiple Myeloma •Melanoma •Colorectal Prostate Cancer Chronic Myeloid Leukemia (CML) — Results of a Phase II clinical trial Of 19 patients treated with GVAX CML, 7 had complete remission. •Gleevec was taken for at least one year (range 13-53 months) pre-vaccine and then GVAX CML was administered while the patients remained on a stable dose of Gleevec. ◦19 patients enrolled (median of 72 months of follow-up) ◦13 patients (8 of whom had increasing disease burden before vaccination): ◦12 patients reached their lowest levels of residual cancer cells to date following vaccination ◦7 patients had complete remission "We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," said lead investigator Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. Acute Myeloid Leukemia (AML) — Results of Phase II Patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects. •GVAX AML was accompanied by immunotherapy- ◦54 subjects enrolled ◦28 (52%) received a pre-transplantation GVAX AML dose ◦46 (85%) subjects achieved complete remission during the treatment period. Of these patients, the 3-year relapse-free survival (RFS) rate was: ■47.4% in non-GVAX treated patients ■61.8% in the GVAX-treated group ■Overall survival (OS) rate in all subjects was 57.4% ■Overall survival (OS) rate was 73.4% in the GVAX-treated group ■In summary, patients treated with GVAX had both a relapse-free survival and overall survival rate improvement of approximately 30% compared with the non-GVAX-treated subjects Read more on BioSante’s Cancer Vaccines and clinical trial info at: http://www.biosantepharma.com/ Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/ About InvestorIdeas.com: InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires. About our Biotech investor portal: www.biotechindustrystocks.com BiotechIndustryStocks.com is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories. If you have any questions regarding information in this press release please contact the company listed in the press release. Contact BioSante Pharmaceuticals For Investors: The Trout Group LLC Tricia Swanson (646) 378-2953 tswanson@troutgroup.com or For Media: McKinney/Chicago Alan Zachary (312) 944-6784 ext. 316 azachary@mckinneychicago.com The content from the investor Fact sheet and opinions from http://www.biosantepharma.com/ Disclaimer: The following news is paid for by BPAX (three thousand per month) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Investorideas.com Disclaimer: http://www.investorideas.com/ Investorideas.com Disclosure: http://www.investorideas.com/ Source: Investorideas.com, BioSante, Investorideas.com Contact Investorideas.com to become a biotech showcase stock or research biotech stocks 800 665 0411 cvanzant@investorideas.com # # # InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including energy and mining stocks, addition to global markets including China, India and Australia. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
